[go: up one dir, main page]

Qian et al., 2025 - Google Patents

The role of TIGIT-CD226-PVR axis in mediating T cell exhaustion and apoptosis in NSCLC

Qian et al., 2025

Document ID
1951492435054149136
Author
Qian L
Wu L
Miao X
Xu J
Zhou Y
Publication year
Publication venue
Apoptosis

External Links

Snippet

The treatment of non-small cell lung cancer (NSCLC) remains a critical challenge in oncology, primarily due to the dysfunction and exhaustion of T cells within the tumor microenvironment, which greatly limits the effectiveness of immunotherapy. This study …
Continue reading at link.springer.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Li et al. B7-H3 promotes gastric cancer cell migration and invasion
Xia et al. EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
Jacoberger-Foissac et al. CD73 inhibits cGAS–STING and cooperates with CD39 to promote pancreatic cancer
Yu et al. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation
CN104857016B (en) Method for identifying compounds useful in the treatment of cancer
Hao et al. Phosphodiesterase 3A represents a therapeutic target that drives stem cell–like property and metastasis in breast cancer
Lin et al. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression
Gao et al. CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer
Li et al. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1
Li et al. TNFR2 deficiency impairs the growth of mouse colon cancer
Shen et al. ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner
Zhang et al. HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer
Hu et al. Enhanced antitumor activity of cetuximab in combination with the Jak inhibitor CYT387 against non-small-cell lung cancer with various genotypes
Zhou et al. CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells
Lin et al. circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma
Meidenbauer et al. Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC
Wen et al. Clusterin-mediated polarization of M2 macrophages: A mechanism of temozolomide resistance in glioblastoma stem cells
WO2024040148A1 (en) Combination treatment for cancer
Chang et al. Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity
Wang et al. EMP2 acts as a suppressor of melanoma and is negatively regulated by mTOR-mediated autophagy
US20160074428A1 (en) Compositions and methods for the treatment of human immunodeficiency virus infection
Qian et al. The role of TIGIT-CD226-PVR axis in mediating T cell exhaustion and apoptosis in NSCLC
CN115515636A (en) Methods and compositions for treating APC-deficient cancers
JP7510144B2 (en) Anticancer drugs and their uses
EP3463474A1 (en) Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer